Trial intelligence / Profile preview

Safety and Efficacy of Botox for Neurogenic Overactive Bladder

NCT00461292Phase 3Completed

Sponsor
Allergan
Start
May 2007
Primary completion
Mar 2010
Modality
Recombinant Proteins and Enzymes
Countries
12
01

Overview

A Phase 3 trial of onabotulinumtoxinA in Neurogenic Bladder (NB), sponsored by Allergan. Started May 2007; status: completed.

02

Drugs

onabotulinumtoxinA
03

Conditions

Neurogenic Bladder (NB)

Beyond the preview

Go deeper on NCT00461292.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00461292.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call